Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
crispr
14
×
life sciences
national blog main
national top stories
14
×
boston blog main
boston top stories
biotech
san francisco blog main
san francisco top stories
national
new york blog main
boulder/denver blog main
boulder/denver top stories
cancer
detroit blog main
detroit top stories
new york top stories
raleigh-durham blog main
raleigh-durham top stories
san diego blog main
san diego top stories
seattle blog main
seattle top stories
texas blog main
texas top stories
wisconsin blog main
wisconsin top stories
deals
fda
indiana blog main
indiana top stories
editas medicine
ipo
novartis
startups
clinical trials
eli lilly
gene editing
gene therapy
glaxosmithkline
What
bio
roundup
crispr
new
gene
cas
life
medicine
medicines
moves
science
therapeutics
years
big
cancer
car
ceo
companies
develop
diagnostics
editing
human
ipo
known
mammoth
millions
month
patients
remains
talk
therapy
today
week
access
acquisitions
advanced
allogene
announced
approval
available
Language
unset
unknown
Current search:
crispr
×
" national top stories "
×
@xconomy.com
4 years ago
Bio Roundup: Gilead’s $4.9B Deal, COVID-19 Collabs, IPO Plans & More
@xconomy.com
4 years ago
CRISPR, CAR-T, Consolidation: Top Advanced Therapy Milestones of 2019
@xconomy.com
4 years ago
Bio Roundup: Mammoth Moves, Black Diamond’s Pop, Ohana’s Debut & More
@xconomy.com
4 years ago
With $45M, Mammoth Bio Expects Big Things From Tiny CRISPR Cas14
@xconomy.com
4 years ago
Bio Roundup: Ichnos Emerges, Beyond CAR-T, BridgeBio Bails & More
@xconomy.com
4 years ago
Jeff Leiden, Who Shaped Vertex Into a CF Force, to Switch Roles
@xconomy.com
4 years ago
Bio Roundup: Michael Becker, Suzanne Eaton, Gene Therapy Moves & More
@xconomy.com
5 years ago
Laurie Glimcher To Headline Xconomy Keynote Series in Boston in September
@xconomy.com
5 years ago
Bio Roundup: Biogen’s Strategy, Drug Price Convo, NASH News & More
@xconomy.com
5 years ago
CRISPR Diagnostic Race Heats Up as Sherlock Bio Launches With $35M
@xconomy.com
5 years ago
Bio Roundup: New CRISPR Feud, A NY Splash, Pharma vs. Congress & More
@xconomy.com
5 years ago
Bio Roundup: Bosley’s Editas Exit, Bridge Bucks, CRISPR Crime & More
@xconomy.com
5 years ago
Bio Roundup: BIO Diversity, Allogene IPO, CRISPR In Utero & More
@xconomy.com
6 years ago
CRISPR Risks? Researchers Stoke Fears of Cancer in Gene-Edited Cells